Loading…
Pulmatrix, Inc. is projected to rise to $1.94 by 2027, a +13% move from its current price of $1.72. PULM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.67 | $1.72 | $1.78 | -0.03% |
| Jul 15 | $1.64 | $1.72 | $1.80 | -0.06% |
| Jul 16 | $1.63 | $1.72 | $1.82 | -0.08% |
| Jul 17 | $1.61 | $1.72 | $1.83 | -0.11% |
| Jul 18 | $1.60 | $1.72 | $1.85 | -0.14% |
| Jul 19 | $1.59 | $1.72 | $1.86 | -0.17% |
| Jul 20 | $1.58 | $1.72 | $1.87 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.58 | $1.72 | $1.87 | -0.20% |
| Week 2 | $1.52 | $1.71 | $1.93 | -0.39% |
| Week 3 | $1.48 | $1.71 | $1.98 | -0.59% |
| Week 4 | $1.44 | $1.71 | $2.02 | -0.78% |
| Week 5 | $1.41 | $1.70 | $2.06 | -0.97% |
| Week 6 | $1.38 | $1.70 | $2.09 | -1.17% |
| Week 7 | $1.36 | $1.70 | $2.12 | -1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pulmatrix, Inc. is a healthcare company focused on the development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. It offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.
The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Pulmatrix, Inc. is a healthcare company focused on developing inhaled therapeutic products for migraine and respiratory diseases with unmet medical needs in the United States.
The stock trades at $1.72 per share, with a market capitalization of $6.28M, and it ranks 5259 by market cap.
The forecast suggests a long-term price outlook with substantial upside by 2050, including an average price of $12.40 and a maximum of $24.42 in 2050, implying a ROI of up to 621.1% and a bullish long-term trajectory.
Key milestones in the forecast show gradual upside, with 2026 average price at $1.72 and notable expansion toward the 2040s and 2050s, culminating in a much higher long-run average of $12.40.
A major floor 39.5% below — a decisive break under it would weaken the trend.
The nearest floor, 25.0% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 44.8% above — clearing it would confirm fresh momentum.
Key PULM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PULM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.77 | Sell | $1.76 | Sell |
| MA 10 | $1.73 | Sell | $1.72 | Buy |
| MA 20 | $1.61 | Buy | $1.63 | Buy |
| MA 50 | $1.43 | Buy | $1.56 | Buy |
| MA 100 | $1.66 | Buy | $1.83 | Sell |
| MA 200 | $2.73 | Sell | $2.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.19 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 58.69 | Neutral |
| Williams %R (14) | -42.11 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 14.67 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 57.89 | Neutral |
| TRIX (15) | 0.94 | Buy |
| Awesome (5,34) | 0.27 | Buy |
| Ultimate (7,14,28) | 58.18 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 1.82 | Sell |
| ADX (14) | 29.47 | Buy |
| ATR (14) | 0.05 | Info |
The near-term technical picture is bullish, with sentiment labeled as BULLISH and an RSI(14) of 60.
Price action is trading above the 50-day simple moving average (SMA50) at $1.43, suggesting some near-term strength, while the 200-day simple moving average (SMA200) sits at $2.73, indicating a longer-term resistance relative to the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.72 | $2.26 | 0% | Neutral | |
| $1.52 | $1.94 | $2.64 | +13% | Neutral | |
| $1.67 | $2.21 | $3.13 | +28% | Bullish | |
| $1.51 | $2.05 | $3.00 | +19% | Neutral | |
| $1.75 | $2.44 | $3.67 | +42% | Bullish | |
| $2.32 | $3.30 | $5.10 | +92% | Bullish | |
| $2.45 | $3.55 | $5.60 | +107% | Bullish | |
| $2.60 | $3.85 | $6.19 | +124% | Bullish | |
| $2.63 | $3.97 | $6.50 | +131% | Bullish | |
| $2.60 | $4.00 | $6.66 | +133% | Bullish | |
| $4.00 | $6.69 | $11.92 | +289% | Bullish | |
| $6.40 | $12.40 | $24.42 | +621% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.19 | $1.72 | $2.10 | +0.00% |
| August 2026 | $1.46 | $1.73 | $2.11 | +0.50% |
| September 2026 | $1.40 | $1.68 | $2.07 | -3.00% |
| October 2026 | $1.43 | $1.72 | $2.15 | +2.75% |
| November 2026 | $1.47 | $1.79 | $2.25 | +3.62% |
| December 2026 | $1.46 | $1.78 | $2.26 | -0.47% |
Click any year to see its month-by-month PULM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PULM is projected to trade between $1.19 and $2.26, averaging $1.72 — a potential gain of 0% from today's $1.72. A consolidation phase looks the most probable path here.
Pulmatrix, Inc.'s 2027 outlook centres on $1.94, within a $1.52 to $2.64 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2028, PULM could reach as high as $3.13, with a base case around $2.21 and support toward $1.67 — roughly +28% from $1.72. Buyers look set to stay in control over this stretch.
Expect PULM to range from $1.51 to $3.00 through 2029. The $2.05 average target implies a +19% move from current prices. That is -7% versus the projected 2028 average. Price action looks broadly range-bound.
The PULM price prediction for 2030 points to an average of $2.44 (low $1.75, high $3.67) — a potential gain of +42% on today's $1.72. Buyers look set to stay in control over this stretch.
In 2031, PULM is projected to trade between $2.32 and $5.10, averaging $3.30 — a potential gain of +92% from today's $1.72. That is up +36% on the projected 2030 average. Momentum favours further upside here.
Pulmatrix, Inc.'s 2032 outlook centres on $3.55, within a $2.45 to $5.60 range. That is up +8% on the projected 2031 average. That marks a +107% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PULM could reach as high as $6.19, with a base case around $3.85 and support toward $2.60 — roughly +124% from $1.72. Momentum favours further upside here.
Expect PULM to range from $2.63 to $6.50 through 2034. The $3.97 average target implies a +131% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PULM price prediction for 2035 points to an average of $4.00 (low $2.60, high $6.66) — a potential gain of +133% on today's $1.72. Momentum favours further upside here.
In 2040, PULM is projected to trade between $4.00 and $11.92, averaging $6.69 — a potential gain of +289% from today's $1.72. That is up +67% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Pulmatrix, Inc.'s 2050 outlook centres on $12.40, within a $6.40 to $24.42 range. That is up +85% on the projected 2040 average. That marks a +621% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PULM today (≈ 581.395349 PULM) could be worth
$7,211.02
+$6,211.02 (+621%) by 2050 · US Dollar
Based on the average projected PULM price of $12.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PULMwould be worth at today's price.
$1,000 invested in PULM on Jul 10, 2025 (≈ 155.279502 PULM) would be worth
$267.08
-$732.92 (-73.3%) today · 0.27× · US Dollar
Based on a PULM entry price of $6.44 vs. today's $1.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.72 | $1,000 | -0.0% |
| 1 month ago | $1.37 | $1,255.47 | +25.5% |
| 3 months ago | $1.2 | $1,433.33 | +43.3% |
| 6 months ago | $2.35 | $731.91 | -26.8% |
| 1 year ago | $6.44 | $267.08 | -73.3% |
| All time (5.0y) ago | $17.34 | $99.19 | -90.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PULM forecast.
Our base-case forecast reaches $3.40 around 2032.
Implied market cap at $3.40: $12.42M
The multi-year forecast points to a rising average price from $1.72 in 2026 to $12.40 by 2050, with the potential maximum reaching $24.42 in 2050. This trajectory reflects a sustained long-term upside, supported by higher annualized return targets as the years progress.
In 2030, the average forecast is $2.44 with a 41.7% ROI, and the sentiment is BULLISH. The path continues higher through 2031 ($3.30 avg, 92.1% ROI) and 2032 ($3.55 avg, 106.7% ROI), then through 2033 ($3.85 avg, 124% ROI), 2034 ($3.97 avg, 131.1% ROI), and 2035 ($4.00 avg, 132.7% ROI). By 2040 the average is forecast at $6.69 with a 289% ROI, and by 2050 the average reaches $12.40 with a 621.1% ROI, all flagged as BULLISH.
These are estimates and not guarantees; actual results will depend on factors in the market and the company’s execution. The figures show a long-run bullish bias, but near-term performance remains uncertain given the low current market capitalization and evolving clinical program outcomes.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $2.44, with a min of $1.75 and a max of $3.67; ROI 41.7%; sentiment BULLISH.
The forecast indicates a bullish longer-term path, with sentiment turning BULLISH in 2030 and remaining so through 2050, and a 2050 ROI of 621.1%. Note that 2026 is Neutral.
Yes—the forecasted maximum prices are $5.10 in 2031, $5.60 in 2032, $6.19 in 2033, and $6.50 in 2034.
Current price is $1.72 and market cap is $6.28M.
Average price is $12.40, with a minimum of $6.40 and a maximum of $24.42; ROI 621.1%; sentiment BULLISH.
Pulmatrix, Inc. Community Discussion
0Share your Pulmatrix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.